PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $21.7 million in its first quarter. On a per-share basis, the Princeton, New Jersey ...

PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $21.7 million in its first quarter. On a per-share basis, the Princeton, New Jersey ...

PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $21.7 million in its first quarter. On a per-share basis, the Princeton, New Jersey ...

Amicus Therapeutics FOLD is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Amicus Therapeutics is bordering on breakeven, according to the 12 American Biotechs analysts. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$8 ...

Amicus Therapeutics has a 12-month low of $7.85 and a 12-month high of $12.65. The business has a 50-day moving average price of $9.19 and a 200 day moving average price of $9.90.

Amicus Therapeutics has a 12 month low of $8.78 and a 12 month high of $14.02. The company has a fifty day simple moving average of $9.58 and a 200 day simple moving average of $10.42.

Analyst Price Forecast Suggests 78.37% Upside As of December 3, 2024, the average one-year price target for Amicus Therapeutics is $18.10/share. The forecasts range from a low of $14.14 to a high ...